Brett Pletcher Net Worth

The estimated Net Worth of Brett A Pletcher is at least $11.5 Milhão dollars as of 10 June 2022. Mr. Pletcher owns over 782 units of Gilead Sciences stock worth over $2,728,164 and over the last 6 years he sold GILD stock worth over $3,780,468. In addition, he makes $5,032,680 as Executive Vice President, Chief Compliance Officer, General Counsel, e Corporate Secretary at Gilead Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Pletcher GILD stock SEC Form 4 insiders trading

Brett has made over 24 trades of the Gilead Sciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 782 units of GILD stock worth $63,295 on 10 June 2022.

The largest trade he's ever made was exercising 20,000 units of Gilead Sciences stock on 14 November 2019 worth over $486,000. On average, Brett trades about 4,125 units every 30 days since 2018. As of 10 June 2022 he still owns at least 33,706 units of Gilead Sciences stock.

You can see the complete history of Mr. Pletcher stock trades at the bottom of the page.

Brett Pletcher biography

Brett Alan Pletcher serves as Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary of the Company. Mr. Pletcher leads a group at Gilead that includes the government affairs and policy, public affairs, and legal organizations. In his role, he oversees our work to shape health policy and communicate the company’s perspective across external audiences. As General Counsel, he is also responsible for all of the company’s legal functions, including intellectual property, litigation and compliance efforts associated with the promotion of our products. Before joining Gilead in 2005, Mr. Pletcher was a partner in the law firm of Gunderson Dettmer, LLP, where he provided corporate and securities services to emerging growth public and private companies as well as venture capital investors. Mr. Pletcher received his bachelor’s degree in economics and political science from the University of California, Riverside and earned his law degree from the University of California, Berkeley’s Boalt Hall School of Law..

What is the salary of Brett Pletcher?

As the Executive Vice President, Chief Compliance Officer, General Counsel, e Corporate Secretary of Gilead Sciences, the total compensation of Brett Pletcher at Gilead Sciences is $5,032,680. There are 4 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.

How old is Brett Pletcher?

Brett Pletcher is 52, he's been the Executive Vice President, Chief Compliance Officer, General Counsel, e Corporate Secretary of Gilead Sciences since 2019. There are 17 older and 7 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.

What's Brett Pletcher's mailing address?

Brett's mailing address filed with the SEC is 350 OYSTER POINT BLVD, , SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Gilead Sciences

Over the last 21 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger, eJohn F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.

What does Gilead Sciences do?

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Complete history of Mr. Pletcher stock trades at Cytokinetics Inc e Gilead Sciences

Gilead Sciences executives and stock owners

Gilead Sciences executives and other stock owners filed with the SEC include:

• Daniel O'Day,
  Chairman of the Board, Chief Executive Officer
• Johanna Mercier,
  Chief Commercial Officer
• Daniel P. O'Day,
  Chairman & CEO
• Andrew Dickinson,
  Chief Financial Officer, Executive Vice President
• Brett Pletcher,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Johanna Mercier,
  Chief Commercial Officer
• Dr. Merdad V. Parsey M.D., Ph.D.,
  Chief Medical Officer
• Merdad Parsey,
  Chief Medical Officer
• Brett A. Pletcher,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Andrew D. Dickinson,
  Exec. VP & CFO
• Per Wold-Olsen,
  Independent Director
• Richard Whitley,
  Independent Director
• Kelly Kramer,
  Independent Director
• Kevin Lofton,
  Lead Independent Director
• Harish Manwani,
  Independent Director
• Jacqueline Barton,
  Independent Director
• Sandra Horning,
  Independent Director
• Anthony Welters,
  Director
• Javier Rodriguez,
  Director
• Michael Quigley,
  Senior Vice President - Research Biology
• Linda Higgins,
  Senior Vice President - Head of External Innovation
• Jyoti Mehra,
  Executive Vice President of Human Resources
• Dr. Linda Slanec Higgins Ph.D.,
  Sr. VP & Head of External Innovation
• Jyoti K. Mehra,
  Exec. VP of HR
• Deborah H. Telman,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Dr. Diana M. Brainard M.D.,
  Sr. VP of HIV & Emerging Viral Infections
• Dr. Taiyin Yang,
  Exec. VP of Pharmaceutical Devel. & Manufacturing
• Jacquie Ross C.F.A.,
  VP of Investor Relations
• Diane E. Wilfong,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• John Francis Cogan,
  Director
• John W Madigan,
  Director
• Robin L Washington,
  SVP, CFO
• Norbert W Bischofberger,
  SVP, Research
• James R Meyers,
  SVP Comm Ops North America
• Nicholas G Moore,
  Director
• Gayle E Wilson,
  Director
• Kevin Young,
  EVP, Commercial Operations
• Laura Hamill,
  EVP, Worldwide Commercial Ops
• Carla A Hills,
  Director
• Etienne Davignon,
  Director
• Paul Rutherford Carter,
  EVP Commercial Ops
• John C Martin,
  President and CEO
• John F Milligan,
  EVP, Chief Financial Officer
• John G Mc Hutchison,
  Chief Scientific Off/HeadR&D
• James M Denny,
  Director
• Gordon Earle Moore,
  Director
• Kristen Metza,
  SVP, Human Resources
• Gregg H Alton,
  SVP, General Counsel
• Paul Berg,
  Director
• Louis G Lange,
  EVP Cardiovascular Therapeutic
• Taiyin Yang,
  SVP, Pharm Dev & Mfg
• William A Lee,
  SVP Research and PPD
• Anthony Caracciolo,
  SVP
• Caroline Dorsa,
  SVP, Chief Financial Officer
• John J Toole,
  SVP
• George P Shultz,
  Director
• Alan Bruce Montgomery,
  SVP, Respiratory Therapeutics
• Michael K Inouye,
  SVP
• Mark L Perry,
  EVP Operations
• Cordell W Hull,
  Director
• Diane E. Wilfong,
  SVP, Controller & CAO
• Sandra Patterson,
  SVP, Controllership
• Jeffrey Bluestone,
  Director
• Deborah H Telman,
  EVP, Corporate Affairs & GC
• Ted W Love,
  Director